Leap Therapeutics, Inc.
LPTX
$0.2963
-$0.0137-4.42%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -9.24% | -30.48% | 16.45% | 20.02% | 26.81% |
| Total Depreciation and Amortization | -100.00% | 100.00% | -66.67% | -40.00% | 106.32% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 16.70% | 19.31% | -81.70% | -86.13% | -85.05% |
| Change in Net Operating Assets | -109.14% | 159.90% | -48.63% | 609.96% | 416.79% |
| Cash from Operations | -20.02% | -27.26% | -37.82% | -18.93% | -3.95% |
| Capital Expenditure | -- | -- | -- | 100.00% | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -100.00% | -100.00% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -100.00% | -100.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.70% | 138,241.38% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | 100.00% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 97.71% | -- | -10,065.52% | -10,065.52% | -9,837.93% |
| Cash from Financing | -100.38% | 132,378.57% | 124,046.67% | 123,700.00% | 128,186.21% |
| Foreign Exchange rate Adjustments | -396.15% | 82.89% | -548.84% | 242.74% | 89.84% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -366.52% | 52.87% | -554.87% | -835.93% | -2,531.58% |